Bioinformatics Partnering Terms and Agreements

Publication Date November 2011
ISBN n/a
Pages 960
Tables n/a
Figures n/a

PDF £1708 $2680

Single user

 Add to Basket

Provides comprehensive insight into bioinformatics partnering deals and agreements entered into by leading healthcare companies.


The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in bioinformatics partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for bioinformatics

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual bioinformatics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bioinformatics deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.

Bioinformatics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to bioinformatics trends and structure of deals entered into by leading companies worldwide.

Bioinformatics Partnering Terms and Agreements includes:

  • Trends in bioinformatics dealmaking in the biopharma industry since 2007
  • Analysis of bioinformatics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life bioinformatics deals
  • Access to over 1,500 bioinformatics deal documents
  • The leading bioinformatics deals by value since 2007
  • Most active bioinformatics dealmakers since 2007
  • The leading bioinformatics partnering resources

In Bioinformatics Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Bioinformatics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 bioinformatics deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise bioinformatics rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
  • Executive Summary
  • Chapter 1 - Introduction
  • Chapter 2 - Trends in bioinformatics dealmaking
    • 2.1. Introduction
    • 2.2. Bioinformatics partnering over the years
    • 2.3. Bigpharma bioinformatics dealmaking activity
    • 2.4. Bigpharma not active in bioinformatics partnering
    • 2.5. Bioinformatics partnering by deal type
    • 2.6. Bioinformatics partnering by stage of development
    • 2.7. Bioinformatics partnering by disease type
    • 2.8. Average deal terms for bioinformatics partnering
      • 2.8.1 Bioinformatics partnering headline values
      • 2.7.2 Bioinformatics deal upfront payments
      • 2.7.3 Bioinformatic deal milestone payments
      • 2.7.4 Bioinformatic royalty rates
  • Chapter 3 - Leading bioinformatics deals
    • 3.1. Introduction
    • 3.2. Top bioinformatic deals by value
    • 3.3. Top bioinformatics deals involving bigpharma
  • Chapter 4 - Bigpharma bioinformatics deals
    • 4.1. Introduction
    • 4.2. How to use bigpharma bioinformatics partnering deals
    • 4.3. Bigpharma bioinformatics partnering company profiles
      • Abbott
      • Actavis
      • Alcon Labs
      • Allergan
      • Amgen
      • Apotex
      • Astellas
      • AstraZeneca
      • Baxter International
      • Bayer
      • Biogen Idec
      • Boehringer Ingelheim
      • Bristol-Myers Squibb
      • Celgene
      • Cephalon
      • Chugai
      • CSL
      • Daiichi Sankyo
      • Dainnipon Sumitomo
      • Eisai
      • Eli Lilly
      • Forest Laboratories
      • Genzyme
      • Gilead Sciences
      • GlaxoSmithKline
      • Hospira
      • Johnson & Johnson
      • Kyowa Hakko Kirin
      • Lundbeck
      • Menarini
      • Merck & Co
      • Merck KGaA
      • Mitsubishi-Tanabe
      • Mylan
      • Novartis
      • Novo Nordisk
      • Nycomed
      • Otsuka
      • Pfizer
      • Roche
      • Sanofi
      • Servier
      • Shionogi
      • Shire
      • Stada
      • Takeda
      • Teva
      • UCB
      • Warner Chilcott
      • Watson
  • Chapter 5 - Bioinformatics dealmaking directory
    • 5.1. Introduction
    • 5.2. Company A-Z
    • 5.3. By stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Formulation
      • Marketed
    • 5.4. By deal type
      • Asset purchase
      • Bigpharma outlicensing
      • Co-development
      • Collaborative R&D
      • Co-market
      • Contract service
      • Co-promotion
      • CRADA
      • Cross-licensing
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Litigation
      • Loan
      • Manufacturing
      • Manufacturing - OEM
      • Marketing
      • Option
      • Promotion
      • Research
      • Settlement
      • Spin out
      • Sub-license
      • Supply
      • Cardiovascular
      • Central Nervous System
      • Cosmetics
      • Dental
      • Dermatology
      • Gastrointestinal
      • Genetic disorders
      • Genitourinary
      • Hematology
      • Hormonal
      • Hospital care
      • Immunology
      • Infectives
      • Inflammatory
      • Metabolic
      • Musculoskeletal
      • Oncology
      • Ophthalmics
      • Respiratory
      • Sensory organs
  • Chapter 6 - Partnering resource center
    • 6.1. Online partnering
    • 6.2. Partnering events
    • 6.3. Further reading on dealmaking
      • Appendices
      • Appendix 1 - Deal type definitions
      • Appendix 2 - Example bioinformatics partnering agreement
      • About Wildwood Ventures
      • Current Partnering
      • Current Agreements
      • Recent report titles from CurrentPartnering
      • Order Form - Reports
  • Table of figures
    • Figure 1: Bioinformatics partnering since 2007
    • Figure 2: Bigpharma - top 50 - bioinformatics deals 2007 to 2011
    • Figure 3: Inactive bigpharma in bioinformatics partnering 2007-2011
    • Figure 4: Bioinformatics partnering by deal type since 2007
    • Figure 5: Bioinformatics partnering by deal type since 2007
    • Figure 6: Bioinformatics partnering by disease type since 2007
    • Figure 7: Bioinformatics partnering by oncology target since 2007
    • Figure 8: Bioinformatics deals with a headline value - by stage of development
    • Figure 9: Bioinformatics deal headline value distribution - discovery stage, US$million
    • Figure 10: Bioinformatic deal headline value distribution - discovery stage, US$million - detail
    • Figure 11: Bioinformatic deals with upfront payment values - by stage of development
    • Figure 12: Bioinformatic deal upfront payment distribution - discovery stage, US$million
    • Figure 13: Bioinformatic deal upfront payment distribution - discovery stage, US$million - detail
    • Figure 14: Bioinformatic deals with milestone payments
    • Figure 15: Bioinformatic deal milestone payment distribution, US$million
    • Figure 16: Bioinformatic deals with royalty rates
    • Figure 17: Top bioinformatics deals by value since 2007
    • Figure 18: Top bioinformatics deals signed by bigpharma value since 2007
    • Figure 19: Online partnering resources
    • Figure 20: Forthcoming partnering events
    • Figure 21: Deal type definitions
    • Figure 22: Bioinformatics partnering agreement between Amgen and IBM, October 2008